PREVEXXION™ RN

The Future is Now

PREVEXXION™ RN is a biological tool effective against very virulent strains of Marek’s disease (MD). The vaccine contains a frozen Marek’s disease chimera consisting of three serotype1 strains. Since Marek’s disease maintains a constant pressure on farms, keeping the disease under control through vaccination is critical.1

Key Advantages

  • Innovative attenuation process delivers the right balance between safety3 & efficacy4
  • Provides protection against very virulent MDV
  • Unprecedented and controlled attenuation process for a Marek’s disease strain that results from different MD virus and LTR gene sequence insertions
  • Administration in ovo or at day-old
  • Compatible with other Marek’s disease vaccines for a customized vaccination program
  • Same convenient application as classic Marek's disease vaccines
  • No reversion to virulence5
  • Package in 5 x 2,000 dose ampules in frozen presentation
  • Do not vaccinate diseased embryonated eggs or birds
  • Administer a full dose to each embryonated egg or to each bird
  • Vaccinate all birds on the premises at one time
  • Avoid stress conditions during and following vaccination
  • Do not place chickens in contaminated facilities
  • Exposure to disease must be minimized as much as possible

PREVEXXION RN References:

  1. Gimeno I.M., 2008, Vaccine, 26S, C31-C41
  2. Witter R.L. & al., 1997, Avian Dis, 41, 407-421
  3. Morrow C., Fehler F. 2004, Marek’s Disease: An Evolving Problem. p 49–61 in Davison F, Nair V. Elsevier, London, United Kingdom
  4. Baigent S., Davison F. 2004, Marek’s Disease: An Evolving Problem. p 52–77 in Davison F, Nair V. Elsevier, London, United Kingdom
  5. Witter R.L. & al., 2002 Dis, 46, 925-937

PREVEXXION™ is a trademark of Boehringer Ingelheim Animal Health USA Inc.
POU-0046-POUL0219

Product Resources

Contact Information

  • Boehringer Ingelheim Animal Health USA Inc.

    Poultry Business Unit

    3239 Satellite Blvd.
    Duluth, GA 30096